Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caliway Biopharmaceuticals Co has a Cash Ratio of 57.87. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Caliway Biopharmaceuticals Co's Cash Ratio or its related term are showing as below:
TPE:6919'
s Cash Ratio Range Over the Past 10 Years
Min: 0.2 Med: 43.95 Max: 183.32
Current: 57.87
During the past 7 years, Caliway Biopharmaceuticals Co's highest Cash Ratio was 183.32. The lowest was 0.20. And the median was 43.95.
TPE:6919's Cash Ratio is ranked better than 99.27% of 1379
companies
in the Biotechnology industry
Industry Median: 2.97
vs TPE:6919: 57.87
Caliway Biopharmaceuticals Co (TPE:6919) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Caliway Biopharmaceuticals Co Cash Ratio Related Terms
Caliway Biopharmaceuticals Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6919 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliway Biopharmaceuticals Co Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Caliway Biopharmaceuticals Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliway Biopharmaceuticals Co (TPE:6919) has a Cash Ratio of 57.87 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Caliway Biopharmaceuticals Co and its competitors. This is 32% above median its historical median of 43.95. Over the past decade, Caliway Biopharmaceuticals Co's Cash Ratio has ranged from 0.20 to 183.32. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #10 out of 1379 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Caliway Biopharmaceuticals Co's Cash Ratio too high?
Caliway Biopharmaceuticals Co's current Cash Ratio of 57.87 is 32% above median its 10-year median of 43.95. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 183.32. The Biotechnology industry median Cash Ratio is 2.97. Caliway Biopharmaceuticals Co's value of 57.87 is 1848.5% above this industry median. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #10 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #10 out of 1379 companies for Cash Ratio. This places Caliway Biopharmaceuticals Co in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.97. Caliway Biopharmaceuticals Co's value of 57.87 is 1848.5% above this benchmark. Historically, Caliway Biopharmaceuticals Co's own Cash Ratio has ranged from 0.20 to 183.32 over the past decade. While the company's 10-year median is 43.95 vs. the industry median of 2.97, Caliway Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.97, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caliway Biopharmaceuticals Co's current Cash Ratio of 57.87 is 1848.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Caliway Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caliway Biopharmaceuticals Co's current Cash Ratio is 57.87, which is 32% above median its own 10-year median of 43.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.03, compared to a current price of NT$94.80 — trading 60.6% above its estimated fair value. The current Cash Ratio is 57.87, which is 32% above median its 10-year median of 43.95 and 1848.5% above the Biotechnology industry median of 2.97. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current Cash Ratio is 57.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of NT$94.80 is trading 60.6% above its estimated GF Value™ of NT$59.03.
GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for TPE:6919:
Cash Ratio: 57.87 (32% above median its 10-year median of 43.95)
GF Value™: NT$59.03 vs. price of NT$94.80 (60.6% above fair value)
Industry Position: 1848.5% above the Biotechnology median (#10 of 1379)
No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score
Get the complete analysis for TPE:6919
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6919 has been successfully added to your 
